Table 3. Randomized studies on combination ADT/RT for intermediate-risk prostate cancer.

Study	Inclusion	Radiotherapy dose	ADT duration NAJ + CC + ADJ (months)	Overall survival; cause specific survival	Significant toxicity differences (ADT vs. none)
RTOG 94-08†	cT1b-T2b, PSA <20	EBRT 66.6 Gy to prostate	2+2+0=4	62% vs. 56% @ 10 yrs; 96% vs. 92% @ 10 yrs	GI, GU, endocrine, cardiac, dermatologic, and hematologic measured: Gr. 3 new impotence 27% vs. 23%
Harvard/DFCI†	cT1b-T2b, PSA ≥10, Gleason ≥7	EBRT 70 Gy to prostate	2+2+2=6	74% vs. 61% @ 8 yrs; not reported (improved hazard ratio)	GI, GU, endocrine, dermatologic measured: Gr. 1 Gynecomastia (18% vs. 3%); Gr 3 new impotence (27% vs. 20%)
GETUG 14	Intermediate-risk	EBRT 80 Gy to prostate	2+2+0=4	NS; not reported	GI, GU measured: no differences
RTOG 0815	NCCN intermediate-risk except pts with all 3 risk factors & ≥50% positive cores	EBRT 79.2 Gy to prostate OR	2+2+2=6	Pending report	Pending report

^†, some patients on these trials were high-risk. All trials use GnRH agonist + antiandrogen for ADT. NAJ, neoadjuvant; CC, concurrent; ADJ, adjuvant; NS, not statistically significant; ADT, androgen deprivation therapy; NCCN, National Comprehensive Cancer Network; EBRT, external beam radiation therapy; GnRH, gonadotropin releasing hormone; PSA, prostate-specific antigen, GI, gastrointestinal; GU, genitourinary.